When Approvable Is Good News: Forest Gets January Launch for Bystolic

Is there a way out of the woods for new drug sponsors seeking FDA approval for products with broad primary care indications? Forest may have found a path with nebivolol, but the formula is not one that will excite many other drug sponsors.